Adalimumab biosimilar - Samsung Bioepis

Drug Profile

Adalimumab biosimilar - Samsung Bioepis

Alternative Names: Imraldi; SB-5

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samsung Bioepis
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Ankylosing spondylitis; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis

Most Recent Events

  • 24 Aug 2017 Registered for Ankylosing spondylitis in European Union, Norway, Norway, Liechtenstein, Iceland (SC)
  • 24 Aug 2017 Registered for Crohn's disease (In children) in European Union, Liechtenstein, Norway, Iceland (SC)
  • 24 Aug 2017 Registered for Crohn's disease in European Union, Liechtenstein, Norway, Iceland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top